spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

Oxford Genetics

They will allow Twist Bioscience to clone synthesized DNA for its diverse customer base

November 16, 2017, Oxford, England and San Francisco, Calif. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.

Dr Ryan Cawood, CEO of Oxford Genetics said, “This license agreement with Twist Bioscience serves as further recognition of our approach to developing the best optimised expression vectors. By utilising our SnapFast™ platform, Twist Bioscience is giving its customers access to the latest vector designs for the most demanding applications and providing them with better value, a streamlined workflow and maximum flexibility in order to utilise their custom DNA constructs to their best effect.”

Oxford Genetics specialises in the design of application specific vectors, which is a culmination of access to cutting edge bioinformatics, generation of extensive biological data, and continual refinement to ensure customer success. The vectors also grant access to the wider SnapFast™ ecosystem which allows Twist Bioscience to switch between all of Oxford Genetics’ vectors, making future changes and additions simple and efficient.

Emily M. Leproust PhD, CEO of Twist Bioscience, commented: “By complementing our ability to provide high throughput synthetic genes with a wide range of customized vectors from Oxford Genetics, we accelerate our customers' workflow, allowing them to solve more complex problems while saving both time and resources. Importantly, it enables us to reach the large group of customers who order smaller quantities of genes in standard vectors. We remain committed to optimizing our product line to enable our customers to succeed more quickly.”

Oxford Genetics Media Contact
Kate Hindhaugh
ramarketing
+44 (0) 7702 433450
kate@ramarketingpr.com

Twist Bioscience Corporation Contacts

Investors
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact
Angela Bitting
925-202-6211
media@twistbioscience.com

About Oxford Genetics
Oxford Genetics, headquartered in Oxford, UK, is a leading synthetic biology company dedicated to the creation of biology-based technologies to aid in the discovery and development of biologics, cell and gene therapies. Founded in 2011, the company has experience in DNA design for the optimisation of protein expression, improved viral delivery systems and cell line engineering.
 
About Twist Bioscience Corporation
At Twist Bioscience Corporation, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com. Sign up to follow our Twitter feed @TwistBioscience.
phone +44 (0) 1865 309 664
web www.oxfordgenetics.com
email Oxford Genetics Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Laboratory Gains ISO 17025 Accreditation for Transit Simulation

Medical Engineering Technologies’ packaging laboratory now has ISTA 2A and ASTM D4169 transit testing added to its accreditation.
More info >>


White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

BIO-Europe 2018-24th Annual International Partnering Conference

5-7 November 2018, Bella Center Copenhagen, Denmark

The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement